The Federal Government has taken a bold step to end the overdependence on imported insulin.
Through the Ministry of Innovation, Science & Technology and its research arm NABRDA, Nigeria has signed a landmark agreement with Shanghai Haiqi Industrial Company of China to establish local insulin production. This historic partnership means:
Cheaper, more accessible insulin for patients; Stable supply of life-saving medication; Technology transfer & job creation; and Strengthened local biotech capacity.
For years, high costs and erratic imports made diabetes care difficult. Now, under President Tinubu’s Renewed Hope Agenda, Nigeria is positioning itself as a regional hub for biotechnology and healthcare innovation.
NTA news
